Dr. Kenneth Aldape from the U.S. National Cancer Institute Joins Pangea Biomed’s Scientific Advisory Board

Pangea Biomed, the startup behind the world’s most advanced cancer response predictor, ENLIGHT, announced that Dr. Kenneth D. Aldape, M.D., has joined the company’s scientific advisory board.

Dr. Aldape, a globally recognized molecular neuropathologist, is Chief of the National Cancer Institute (NCI) Lab of Pathology. He is a leading figure in his field, esteemed for his influential work using methylation patterns (chemical modifications) for the sub-classification of brain tumors, which is considered the most accurate tool for brain tumor diagnosis.

“We’ve been collaborating with Dr. Aldape for years, around NCI trials to test our ENLIGHT platform,” explained Pangea CEO Tuvik Beker. “Now, with him on our scientific advisory board, we’re excited for his strategic expertise and input in shaping the direction of our research and development efforts.”

Dr. Aldape has previously held faculty positions at the University of California, San Francisco, at MD Anderson Cancer Center, where he served as department chair of pathology and at Princess Margaret Cancer Centre, where he served as a senior scientist. He is recognized as a leader in the use of molecular technologies to advance precision tumor diagnostics.

“As an advisor to Pangea, I look forward to gaining an even better understanding of the capabilities of improved cancer diagnostics and treatments for patients,” said Dr. Aldape. “As we work closely together, we hope to generate new technologies that contribute to patient welfare.”

Dr. Aldape’s role as a Pangea scientific advisory board member is recognized as part of his official duties by The National Institutes of Health (NIH), ensuring it aligns with his responsibilities within the organization and in external collaborations.

Dr. Aldape’s appointment to Pangea’s scientific advisory board closely follows that of Dr. Lillian Siu, a senior medical oncologist at Princess Margaret Cancer Centre, professor of medicine at the University of Toronto and the current president of the American Association for Cancer Research (AACR).

In addition to Dr. Aldape and Dr. Siu, the scientific advisory board includes:

• Raanan Berger, MD, Ph.D., Director of the Cancer Center at Sheba Medical Center

• J. Silvio Gutkind, Ph.D., Professor and Chair of the Department of Pharmacology at UCSD School of Medicine and Associate Director for Basic Science at Moores Cancer Center

• Dan A. Landau, MD, Ph.D., Assistant Professor at Weill Cornell Medical College and Core Member at the New York Genome Center

• Gideon Rechavi, MD, Ph.D., head of Sheba Cancer Research Center and head of the Wohl Institute for Translational Medicine

• Ze’ev Ronai, Ph.D., Director of the NCI-Designated Cancer Center at Sanford Burnham Prebys Discovery Institute

• Eytan Ruppin, MD, Ph.D., Chief of the Cancer Data Science Lab at the National Cancer Institute

To learn more about Pangea and ENLIGHT, please visit https://pangeabiomed.com

About Pangea Biomed

Founded in 2018, Pangea Biomed developed ENLIGHT – the world’s most advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world. Pangea aims to bring effective precision oncology to cancer patients, improve oncology drug development and empower oncologists to treat patients with success. Pangea is backed by NFX, and its technology has been published in leading journals, including Cell, Med, Science Advances, Cancer Cell, Journal for ImmunoTherapy of Cancer and Nature Communications.

Contact Information

VSC

Media Contact

VSC for Pangea Biomed

pangea@vsc.co